Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
September 01, 2022 16:05 ET
|
Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
Revolution Medicines to Participate in Upcoming Investor Conferences
August 31, 2022 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Nocera, Inc. Announces Second Quarter 2022 Financial Results
August 23, 2022 08:00 ET
|
Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Nocera, Inc. (NASDAQ: NCRA) (“Nocera” or the “Company”), a fully integrated sustainable seafood company with a focus on manufacturing and...
Blue Star Foods Reports Revenue Growth of 79% for First Half of 2022
August 16, 2022 07:30 ET
|
Blue Star Foods Corp.
Highlighted by Initial $0.5 Million Revenue from Soft-Shell Crab RAS Miami, FL, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ:...
Nocera, Inc. Announces Closing of $6.58 Million Underwritten Public Offering
August 15, 2022 12:41 ET
|
Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Nocera, Inc. (NASDAQ: NCRA) (“Nocera” or “the Company”), a fully integrated sustainable seafood company with a focus on manufacturing and...
Nocera Announces Pricing of $6.58 Million Public Offering, Nasdaq Listing and Reverse Stock Split
August 10, 2022 18:45 ET
|
Nocera, Inc
TAIPEI CITY, Taiwan, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Nocera, Inc. (OTC: NCRA; NASDAQ: NCRA) (“Nocera” or “the Company”), a fully integrated sustainable seafood company with a focus on...
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
August 09, 2022 16:02 ET
|
Revolution Medicines, Inc.
First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers ...
Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022
July 28, 2022 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 22, 2022 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
July 19, 2022 22:41 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...